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The Redelberger antigen (Rba) was first discovered in 1974 on the
RBCs of a blood donor who was an employee of the Community
Blood Center in Dayton, Ohio. The discovery was made as a result
of the investigation of a reagent contamination problem. Two
examples of the Rba antigen were subsequently identified in the
United Kingdom,but no “new”examples have been identified in the
United States or Europe. Anti-Rba is a commonly occurring
antibody, often found in combination with other antibody
specificities, especially in combination with other antibodies to
low-incidence antigens. Immunohematology 2006;22:48–51.
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The discoveries of antigens of low incidence have
historically occurred as a result of one of several
scenarios. These scenarios include the following: an
infant suffering from HDN due to a maternal antibody
against a low-incidence antigen of paternal origin, a
patient who experiences an unexpected transfusion
reaction, a patient whose serum has an unexpected
antibody detected in a screening or compatibility test,
an individual whose RBCs react unexpectedly with
routine blood grouping reagents, and the antithetical
antigen to a defined high-incidence antigen.
Investigations of low-incidence antigens are often time-
consuming, and, unfortunately, often dismissed by
blood bankers because low-incidence antigens are
perceived as only of academic, not practical, interest.
This article will review the discovery of a very rare
antigen, Redelberger, or Rba. It will also document the
subsequent discoveries of the Rba antigen in the United
States and how all of the individuals in the United
States whose RBCs carry Rba can be traced back to the
original propositus.
Background
In March 1974, Richard Redelberger donated a unit
of blood at the Community Blood Center in Dayton,
Ohio. Mr.Redelberger was a frequent blood donor who
was employed, quite coincidentally, by the Community
Blood Center of Dayton as a donor services
coordinator. Mr. Redelberger’s RBCs routinely typed as
group B, D–, but on this particular donation, his RBCs
reacted 3+ at the antihuman globulin phase of testing
with a commercial anti-CDE reagent supplied by
Gamma Biologicals, Inc., of Houston, Texas. Other lot
numbers of Gamma anti-CDE reagent did not react
with Mr. Redelberger’s RBCs nor did anti-CDE reagents
from other commercial manufacturers. Gamma was
contacted about this potential contamination problem
and the unidentified antibody was traced to the anti-E
component of the reagent.1
The anti-E component of the anti-CDE reagent and
samples of Mr. Redelberger’s RBCs were sent to many
reference laboratories around the world. Initially, it was
thought that the antigen present was the previously
identified Bishop antigen (Bpa). However, with further
testing, all investigators soon agreed that the antigen
present on the Redelberger RBCs was unique. Mr.
Redelberger’s RBCs reacted with the Tillett serum
(which contains many antibodies to low-incidence
antigens), as did the RBCs of a random donor from the
North London Blood Transfusion Center in London,
England. RBCs from this donor,Mrs.NM,gave the same
pattern of reactions with a battery of antisera for low-
incidence antigens as did those from Redelberger; Mrs.
NM was subsequently determined to be the second
individual identified as possessing RBCs with the “new”
antigen. A third donor, Mrs. SR, was found at the Wales
Blood Transfusion Center in Cardiff. The RBCs from
this donor reacted with only one of several anti-E sera.
Further investigation revealed that her RBCs gave the
same pattern of reactions with antibodies to low-
incidence antigens as did those of Redelberger and
Mrs. NM.1
The Redelberger antigen was studied in all three
families and was found to be autosomal dominant in its
inheritance.1 Richard Redelberger was thrilled to learn
that a “new” antigen had been discovered on his RBCs.
Always the master of the one-liner, Richard declared
that he knew all along that he could “never be a
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Redelberger antigen
bishop!” The antigen was subsequently named in his
honor and abbreviated as Rba according to the
conventions of the time.
No new examples of the Redelberger antigen were
reported for many years in either the United States or
Europe. However, anti-Rba was found with some
frequency, suggesting that the antibody is usually
naturally occurring. It has been demonstrated that
most examples of anti-Rba are direct agglutinins and
predominantly IgM. In one study,6200 donor sera were
screened for the presence of anti-Rba and six examples
were found.1,2 The incidence of anti-Rba is much higher
in sera containing multiple antibodies, especially when
multiple antibodies to low-incidence antigens are
present. Anti-Rba is especially common in sera that
contain anti-Bpa and anti-Wra.1
At the American Red Cross/AABB
Immunohematology Reference Laboratory (IRL)
conference held in Memphis,Tennessee, in April 2004,
Marilyn Moulds of Gamma reported that an apparent
new Rba propositus had been identified. The
individual, RT, was a healthy blood donor who had
donated a unit of RBCs at the Blood Connection in
Greenville, South Carolina. The most probable Rh
genotype of his RBCs was R2R2 and they were
subsequently used by Gamma as part of a reagent RBC
screening duet. Within days of the release of the
screening duet, Gamma received numerous customer
complaints about this particular RBC reacting with
many patient sera when subsequent antibody
identification studies did not detect any alloantibodies.
One hospital reported seven reactive sera with four of
the seven patients reporting no history of transfusion.
A second hospital reported that five of six patient sera
reacted with the RBC over a weekend!  Marilyn’s
investigation focused on the identification of an
antigen of low incidence on the RBCs in question and,
with the assistance of Gail Coghlan of the Rh
Laboratory, University of Manitoba, Winnipeg, in
Manitoba, Canada, they were found to be Rb(a+)
In the audience at the IRL conference that day was
Nancy Lang, the lead technologist in the IRL at the
Community Blood Center/Community Tissue Services
in Dayton, Ohio. Nancy listened to the facts of
Marilyn’s discovery with particular interest since she
personally knew of the discovery of the Redelberger
antigen in Dayton. Upon returning to work on the
Monday morning after the conference, Nancy opened
an e-mail message from a local blood donor, GK. The
message, in part, read:
“I received an e-mail from my sister in Greensboro,
NC, who indicated that her son in Greenville, SC, was
recently told that he had a particular antigen in his
blood associated with the Diego Blood Group . . . I
know that many years ago the Dayton Blood Center
told my mother that she was a carrier of some rare type
of blood component but none of us knew what this
meant . . . I was wondering if you would be willing to
test my blood for this antigen since I am a regular
donor. Apparently, the test involves Rb(a)—whatever
that may be.”
What timing!  Nancy called GK and was able to
confirm that GK’s mother was Richard Redelberger’s
sister. Nancy’s second phone call was to Marilyn
Moulds to tell her the Rba discovery was not a “new”
family in the United States!
A Manufacturer’s Perspective
Often, blood bankers are simply annoyed at the
finding of an antibody directed at a low-incidence
antigen when performing routine serologic
procedures. Very little, if any, effort is put forth in
attempting to identify the specificity of this antibody.
Seen as an isolated event, identification seems
unnecessary and not useful, so the reactivity is ignored
unless a pattern or trend is noted. As a result, potential
“new” low-incidence antigens are not identified as
frequently as they might be. There is one instance
where identification might be pursued, however, and
that is in the case of potential for clinical HDN in a
current pregnancy or for future pregnancies.
Manufacturers of commercial RBC products and
antisera have an entirely different perspective,
however. As illustrated in the case of the R2R2 donor
above, an antibody to a low-incidence antigen can be
quite common, although the incidence of the antigen
itself is very low. Anti-Wra, for example, is analogous to
anti-Rba in that the antibody is quite common while the
antigen itself is very uncommon. The use of a
screening or panel (antibody identification) RBC that
possesses a low-incidence antigen can prove to be
quite frustrating for the unsuspecting customer of the
product when the corresponding antibody occurs with
some frequency. Complaints are generated and sent to
the manufacturer, which launches an investigation of
the antigen on the RBC.
The presence of an antibody to a low-incidence
antigen is not of great concern to the manufacturer of
commercial antisera if the incidence of the antigen is
extremely low. In fact, commercial reagent antisera
only need to be screened for the presence of
antibodies directed at rare antigens that occur in 1
percent or more of the random population. However,
commercial antisera “contaminated” with anti-Rba led
to the initial discovery of the Rba antigen and the
accidental discovery of the Rba antigen in another
member of the Redelberger family was also the result
of an anti-D contamination problem. That story
follows.
AR was a female blood donor from Florida who had
donated to the 6-gallon benchmark. Donor records
showed that she had been typed as D– on all donations
until the last. At that time, in August 2003, the RBCs of
AR reacted weakly in the weak D test with one source
of anti-D reagent, which was a human polyclonal
reagent. Her RBCs did not react with anti-D reagent
used in an automated test and did not react in tube
tests that used monoclonal blend anti-D reagent.
An investigation was launched by the manufacturer
of the anti-D reagent that caused the positive weak D
test result. The RBCs of AR did not react with six
monoclonal anti-D reagents from different
manufacturers but did react with three of 12 human
sera containing multiple antibodies directed at low-
incidence antigens. Several antibodies were in all three
reactive sera. After testing with her standard panel of
sera containing multiple antibodies,Gail Coghlan of the
Rh Laboratory suggested that this donor’s RBCs might
also be Rb(a+). Donor RBCs, known to be D–, Rb(a+),
from a liquid nitrogen collection were then tested and
found to react with the same human polyclonal anti-D
reagent that reacted with AR’s RBCs. Another lot
number of anti-D reagent that contained serum from
the same donor was also found to react with AR’s RBCs
and with the D–, Rb(a+) frozen RBCs.
The referring donor center in Florida was
contacted to obtain more information on AR. AR
indicated that she knew she was positive for the
Redelberger antigen and produced the paperwork
from the original study. Her mother was a sister of
Richard Redelberger!
The Rba Antigen and Antibody Today
The Rba antigen was assigned to the Diego blood
group system in 1996 and its ISBT symbol (number) is
DI6 (010006).3 The molecular basis for the Rba antigen
was published by Jarolim et al. in 1997.4 They showed
that individuals whose RBCs carry the antigen have a
point mutation in anion exchanger 1 that leads to the
replacement of proline with leucine at amino acid 548.
The antigen is expressed on cord RBCs and the effect
of enzymes on the antigen is variable. The antigen
deteriorates upon storage at 4°C but survives storage in
liquid nitrogen.1 Anti-Rba is predominantly IgM but can
also be IgG.1,3 The antibody does not bind complement
and its clinical significance is doubtful.3 Five Rb(a–)
women, who gave birth to Rb(a+) children, did not
make anti-Rba.1,2 No other data are available.
Summary
The Rba antigen is of extremely low incidence and
has only been discovered in three families in the
world.3 All examples of the Rba antigen found in the
United States since 1974 can be traced back to the
original propositus, Richard Redelberger, for whom the
antigen is named (Fig.1). Anti-Rba has been found to be
a frequent, naturally occurring antibody, however, and
is often found in combination with other antibodies,
especially those directed to antigens of low incidence.
Addendum
The authors have been in contact with the
Redelberger family in regard to the publishing of this
article.While completing the article, an e-mail message
was received from family member JS,a grandnephew of
Richard Redelberger. The message, in part, read as
follows:
“…It made me start thinking about the bone
marrow donation that I did a couple years ago.
The recipient was a non-relative that matched
antigens with mine. Do you think that it could
mean that the recipient also has the
Redelberger antigen?”
No, JS, the recipient did not have the Redelberger
antigen at the time you were selected as the marrow
donor. But the recipient does have the Redelberger
antigen now!
Who says blood banking is boring????
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Fig. 1. Pedigree chart of the Redelberger family.
